| P50 | author | Per Soelberg Sørensen | Q12331359 |
| P2093 | author name string | F Sellebjerg | |
| | M Møller | |
| | H B Søndergaard | |
| | N Koch-Henriksen | |
| | A B Oturai | |
| P2860 | cites work | Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis | Q48370561 |
| | Systemic inflammation induces axon injury during brain inflammation. | Q48761733 |
| | Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). | Q50571525 |
| | Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. | Q52022061 |
| | CCR5Delta32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. | Q54641121 |
| | The chemokine receptor CCR5 deletion mutation is associated with MS in HLA-DR4-positive Russians | Q57417484 |
| | Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients | Q24563395 |
| | CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis | Q28271971 |
| | Multiple sclerosis | Q28299151 |
| | Endogenous and recombinant type I interferons and disease activity in multiple sclerosis | Q28728759 |
| | Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis | Q28731914 |
| | Chemokines: a new classification system and their role in immunity | Q29615663 |
| | The many roles of chemokines and chemokine receptors in inflammation | Q29618880 |
| | C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. | Q34967101 |
| | Cutting edge: loss of α4 integrin expression differentially affects the homing of Th1 and Th17 cells | Q35613492 |
| | Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE | Q35669064 |
| | CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions | Q36384816 |
| | Anti-chemokine small molecule drugs: a promising future? | Q37683772 |
| | Association of CCR5 delta32 deletion with early death in multiple sclerosis | Q39015230 |
| | Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. | Q40431316 |
| | CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group | Q41735091 |
| | The CCR5 deletion mutation fails to protect against multiple sclerosis | Q44279950 |
| | Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course. | Q47655510 |
| | Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis. | Q47776071 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 27-31 | |
| P577 | publication date | 2013-05-14 | |
| P1433 | published in | Acta Neurologica Scandinavica | Q4676732 |
| P1476 | title | The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis. | |
| P478 | volume | 129 | |